Objective:To observe the clinical efficacy of rh -endostatin (endostar)combined with capecitabine regimen and capecitabine regimen alone in elderly patients with advanced colorectal cancer.Methods:Totally 86 ca-ses of advanced colorectal cancer elderly patients in our hospital from 2010 to 2013 were randomly divided into the treatment group and the control group,43 cases in each group.Control group was treated by capecitabine regimen a-lone,while treatment group was treated by endostar combined with capecitabine regimen.The short time curative effect,adverse reactions and survival rate of patients in two groups were compared.Results:The effective rate in treat-ment group (44.2%)was higher than that in control group (23.3%)(P<0.05).The clinical benefit rate in treat-ment group (83.7%)was higher than that in control group (55.8%)(P<0.05).There was no statistical signifi-cance in the incidence of leucocyte decreasing,blood platelet decreasing,hand-foot syndrome,nausea and vomiting and diarrhea in two groups (P>0.05).There was also no statistical significance in the incidence of hypertension and serious event in cardiovascular system in two groups (P>0.05 ).1 -year survival rate and 2 -year survival rate in treatment group was higher than those in control group (P<0.05).Conclusion:Endostar combined with capecitabine regimen in the treatment of elderly advanced colorectal cancer will enhance the short time curative effect and survival rate,and with lower adverse reactions.It deserves to be further popularized clinically.%目的：观察卡培他滨单药联合重组人血管内皮抑素（恩度）方案一线化疗老年晚期结直肠癌的临床疗效。方法：选择2010年1月至2013年1月间收治的86例老年晚期结直肠癌患者，随机分为治疗组和对照组，每组43例。治疗组给予卡培他滨单药联合恩度方案，对照组给予卡培他滨单药方案。比较两组患者治疗后的近期疗效、不良反应及生存率。结果：治疗组患者的有效率（44．2％）明显高于对照组（23．3％），治疗组患者的临床获益率（83．7％）明显高于对照组（55．8％），差异有统计学意义（P＜0．05）。治疗组患者的白细胞减少、血小板减少、手足反应、恶心呕吐及腹泻发生率与对照组比较，差异无统计学意义（P＞0．05）。两组患者高血压、心血管等不良事件的发生率比较差异亦无统计学意义（P＞0．05）。治疗组患者的1年生存率和2年生存率均明显高于对照组，差异有统计学意义（P＜0．05）。结论：卡培他滨单药联合恩度方案可提高老年晚期结直肠癌的近期疗效和生存率，不良反应可耐受。
展开▼
